Remdesivir-based therapy improved recovery of patients with COVID-19 in the SARSTer multicentre, real-world study
Flisiak et al.,
Remdesivir-based therapy improved recovery of patients with COVID-19 in the SARSTer multicentre, real-world..,
medRxiv, doi:10.1101/2020.10.30.20215301 (Preprint)
Retrospective study comparing 122 remdesivir patients and 211 lopinavir/ritonavir patients, showing higher rates of clinical improvement with remdesivir and lower mortality (not statistically significant).
[Gérard, Wu, Zhou] show significantly increased risk of acute kidney injury with remdesivir.
all patients, 48.9% lower, RR 0.51, p = 0.18, treatment 5 of 122 (4.1%), control 17 of 211 (8.1%), NNT 25, odds ratio converted to relative risk.
|
SpO2<95%, 58.0% lower, RR 0.42, p = 0.13, treatment 4 of 82 (4.9%), control 14 of 119 (11.8%), NNT 15, odds ratio converted to relative risk.
|
no clinical improvement, 56.5% lower, RR 0.44, p = 0.01, treatment 9 of 122 (7.4%), control 36 of 211 (17.1%), NNT 10, odds ratio converted to relative risk.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Flisiak et al., 3 Nov 2020, retrospective, Poland, preprint, 23 authors.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.10.30.20215301; this version posted November 3, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
Remdesivir-based therapy improved recovery of patients with COVID-19 in the SARSTer
multicentre, real-world study
Robert Flisiak1*#, Dorota Zarębska-Michaluk2*, Aleksandra Berkan-Kawińska3, Magdalena
Tudrujek-Zdunek4, Magdalena Rogalska1, Anna Piekarska3, Dorota Kozielewicz5, Krzysztof
Kłos6, Marta Rorat7,8, Beata Bolewska9, Anna Szymanek-Pasternak10, Włodzimierz
Mazur11, Beata Lorenc12, Regina Podlasin13, Katarzyna Sikorska14, Barbara OczkoGrzesik15, Cezary Iwaszkiewicz16, Bartosz Szetela17, Paweł Pabjan2, Małgorzata
Pawłowska5, Krzysztof Tomasiewicz4, Joanna Polańska18, Jerzy Jaroszewicz15.
*equal contribution
# Corresponding author: Prof. Robert Flisiak, Department of Infectious Diseases and
Hepatology, Medical University of Bialystok, ul. Zurawia 14, 15-540, Bialystok, Poland.
Tel./fax: +48 857416921. Email: robert.flisiak1@gmail.com
1 Department of Infectious Diseases and Hepatology, Medical University of Białystok,
Białystok, Poland
2 Department of Infectious Diseases, Jan Kochanowski University, Kielce, Poland
3 Department of Infectious Diseases and Hepatology, Medical University of Łódź, Łódź,
Poland
4 Department of Infectious Diseases and Hepatology, Medical University of Lublin, Lublin,
Poland
5 Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium
Medicum in Bydgoszcz, Nicolaus Copernicus University, Poland
6 Department of Infectious Diseases and Allergology, Military Institute of Medicine, Warsaw,
Poland
7 Department of Forensic Medicine, Wrocław Medical University, Wrocław, Poland
8 First Infectious Diseases Ward, Gromkowski Regional Specialist Hospital in Wrocław,
Wrocław, Poland.
9 Department of Infectious Diseases, University of Medical Sciences, Poznań, Poland
10 Department of Infectious Diseases and Hepatology, Wrocław Medical University,
Wrocław, Poland
11 Clinical Department of Infectious Diseases in Chorzów, Medical University of Silesia,
Katowice, Poland
12 Pomeranian Center of Infectious Diseases, Department of Infectious Diseases, Medical
University of Gdańsk, Gdańsk, Poland
13 Hospital of Infectious Diseases in Warsaw, Warsaw, Poland
14 Department of Tropical Medicine and Epidemiology, Medical University of Gdańsk,
NOTE: ThisPoland
preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Gdańsk
medRxiv preprint doi: https://doi.org/10.1101/2020.10.30.20215301; this version posted November 3, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
15 Department of Infectious Diseases in Bytom, Medical University of Silesia, Katowice,
Poland
16 Department of Rheumatology and Osteoporosis, Jozef Strus Hospital in Poznań, Poland
17 Department of Infectious Diseases, Liver Diseases and Acquired Immune Deficiencies,
Wrocław Medical University, Wrocław, Poland
18 Department of Data Science and Engineering, Silesian University of Technology, Gliwice,
Poland
medRxiv preprint doi:..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit